ERBB2 and breast cancer: Recent advancements in diagnostic and treatment technologies, such as BRCA1/BRCA2 mutation analysis and targeted therapies against HER2, PD-1, and PD-L1, have significantly improved the prognosis of BC patients [1,3,4].